“The world’s smallest and lightest P-wave centric ECG patch monitor to offer superior signal clarity, greater diagnostic accuracy, and improved patient compliance.”

BardyDx, Inc was founded to address the long-standing complaint in cardiac arrhythmia monitoring that traditional monitors were large, bulky,
uncomfortable, and typically record noisy QRS signals.
Our goal: to completely redesign an arrhythmia monitor
with optimal signal detection, comfort, and ease of use.


Gust Bardy (Chief Executive Officer & Chief Medical Officer)

Gust Bardy, MD serves as Chief Executive Officer and Chief Medical Officer providing strategic direction into all business functions and resources of the company and overseeing the clinical operations at Bardy Diagnostics. Dr. Bardy is a cardiac electrophysiologist with research interests in cardiac defibrillator technology, cardiac arrest, and atrial fibrillation as they affect the public health. He has been a researcher in the field of sudden death and disabling cardiac rhythm disorders for 35 years. Dr. Bardy has also developed technological solutions to patient rhythm problems with hundreds of patents issued globally, most of which have been incorporated in cardiac rhythm management technologies in use by many medical device companies. His primary goals are to help the patient first, the physician second, and other interests third.

Mark Handfelt (Chief Operating Officer)

Mark Querry (Chief Financial Officer)

Mark Querry serves as Chief Financial Officer, overseeing Bardy Diagnostics’ accounting, financial, and human resource functions. Mark has more than twenty years of experience in the medical device industry in a wide variety of roles. Most recently, Mark was Vice President and Chief Financial Officer for Calypso Medical Technologies, Inc., a pioneer in electromagnetic guidance technology used in conjunction with radiation therapy for prostate cancer and other solid tumors. While at Calypso, Mark helped to build out the team, raise capital, implement its reimbursement strategy, and develop leasing solutions for its customers. Prior to Calypso, Mark served as Director of Finance at EKOS Corporation, which developed a unique ultrasound-enabled drug delivery system for treating peripheral blood vessel occlusions. Mark also served as Finance Manager for Abbott Laboratories where he helped establish operating companies in several Eastern European countries. He began his career as an audit professional with Price Waterhouse. Mark earned a BA in English and Accounting from Hillsdale College.

Ken Nelson (Chief Commercial Officer)

Ken Nelson serves as Chief Commercial Officer, leading Bardy Diagnostics’ global sales, marketing, business development, and customer experience functions. His extensive experience in the cardiac monitoring and cardiac rhythm management market includes most recently leading the sales and strategic partnership activities as the US Vice President of Sales and Director of Business Development for BioTelemetry (formerly CardioNet), where he helped transform declining sales to 19 consecutive quarters of revenue and share growth, drastically reduced sales team turnover, and led several high-value strategic partnerships and acquisitions in the cardiac monitoring space. Previously, Ken was national Vice President of Sales and Marketing for iRhythm Technologies, where he built the entire foundational sales and marketing team for the US and substantially grew product sales ten-fold. In addition, he also served at Boston Scientific (formerly Guidant) in their Cardiac Rhythm Management Division for 8 years in various sales leadership roles. Ken earned a BA in Economics from Vanderbilt University.

Bobby Cockrill (Vice President of Sales)

Bobby Cockrill serves as Vice President of Sales, managing all of Bardy Diagnostics’ US sales and business development functions. With over 17 years in the medical device industry, Bobby brings extensive experience in structuring, optimizing, and deploying sales assets from companies of varying sizes from early and late stage start-ups to large-scale businesses. Prior to joining Bardy Diagnostics, Cockrill served as Vice President of Sales at SonoSim, Inc., where he was tasked with reengineering and growing the sales team. In addition, he possesses strong experience in the cardiac device space with various sales leadership positions at Boston Scientific, Cardionet (now BioTelemetry), and Eli Lilly and Company. Bobby graduated from the University of Richmond with dual degrees in Leadership Studies and Rhetoric & Speech Communication. He earned an MBA from the University of Southern California Marshall School of Business.

Chuck Dulken (Vice President of Engineering)

Chuck Dulken serves as the Vice President of Engineering, overseeing product development and advanced development at Bardy Diagnostics. He brings a strong record of leading successful product development efforts, building strong Engineering teams, and championing continuous improvement in the medical device domain in both startup and large company environments, domestic and international. Chuck’s experience includes leading development efforts at Calypso Medical Technologies (Radiation Therapy Localization Systems), Siemens Medical Systems (Diagnostic Ultrasound), and Confirma (MRI Image Processing). Chuck earned a BS in Electrical Engineering from the University of Colorado.


Gust Bardy, MD (Chairman)

Gust Bardy, MD is a cardiac electrophysiologist with research interests in cardiac defibrillator technology, cardiac arrest, and atrial fibrillation as they affect the public health. He has been a researcher in the field of sudden death and disabling cardiac rhythm disorders for 35 years. Dr. Bardy has also developed technological solutions to patient rhythm problems with hundreds of patents issued globally, most of which have been incorporated in cardiac rhythm management technologies in use by many medical device companies. His primary goals are to help the patient first, the physician second, and other interests third.

Alan Levy, PhD (Executive Director)

Alan Levy, PhD brings more than 40 years of senior operational leadership and experience in the medical device industry. Most recently, he served as the Chief Executive Officer and Chairman of the Board at Chrono Therapeutics. In addition, he was a Senior Advisor and Venture Partner of Frazier Healthcare Partners focusing on the Life Science sector. Dr. Levy’s notable previous leadership experiences include serving as the founding Chief Executive Officer at Incline Therapeutics that was acquired by The Medicines Company for $390 million, Chief Executive Officer and President at Northstar Neuroscience that went public and raised $112 million in their IPO, Chief Executive Officer and President at Heartstream that was acquired by Hewlett-Packard for $140 million, and President at Heart Technology that was acquired by Boston Scientific for $500 million. In addition, he held several leadership positions at Ethicon, a division of Johnson & Johnson, including serving as the Vice President of Research and New Business Development and Director.
Dr. Levy serves as a board member of several public and private companies including Intuitive Surgical, Proteus Digital Health and Seattle BioMed. He received his PhD in Organic Chemistry from Purdue University, a BS in Chemistry from City University of New York, and holds an Honorary Doctor of Science from Purdue University.

Paul LaViolette

Paul LaViolette is Managing Partner & Chief Operating Officer of SV Health Investors and heads the firm’s medical device investments. He brings over 35 years of global medical technology management experience. Most recently he was Chief Operating Officer at Boston Scientific. During his 15 years at BSC, Paul served as Chief Operating Officer; Group President, Cardiovascular; President, Cardiology; Group President, Endosurgery; and President, International. The company grew revenue over 20 times during his tenure. Paul integrated two dozen acquisitions and led extensive product development, manufacturing and worldwide commercial organizations. Prior to BSC, he held marketing and general management positions at CR Bard and various marketing roles at Kendall (Medtronic).

Paul currently serves on the boards of Bardy Diagnostics, Baxano Surgical, Cardiofocus, CardioKinetix, Coridea NC2, CSA Medical, DC Devices, Direct Flow Medical, the Medical Device Manufacturers Association (as Chairman), Partners Health System (as Vice Chairman of the Innovation Advisory Board), Thoratec, TransEnterix, ValenTx. He previously served on the boards of Urologix, Percutaneous Valve Technologies and Advamed. Paul received his BA in Psychology from Fairfield University and his MBA from Boston College.

Dave Tamburri

Dave Tamburri is a Managing Partner at Health Enterprise Partners (HEP). Prior to joining HEP, Dave was a Vice President with Susquehanna Growth Equity, a private equity group focused on growth capital opportunities in the technology sector. He was the President and Chief Operating Officer of Onward Healthcare, a Welsh, Carson, Anderson & Stowe portfolio company that provided human capital services to health care providers. Prior to Onward, Dave was an Executive Vice President of Pinnacor, a provider of information and analytical applications where he managed the company’s worldwide operations.
He is currently on the board of directors of Bardy Diagnostics, Catapult Health, eVariant, Jet Health, and Shyft Analytics. Dave previously served on the board of directors for HealthQx (acquired by McKesson), MobileMD (acquired by Siemens Healthcare), Nordic Consulting (recapitalized by Silversmith Capital Partners), Privia Health (merged with Brighton Health), and Vitals. He is on the faculty of Columbia Business School and the School of Professional Studies at Columbia University. Dave is a distinguished graduate of the United States Military Academy and holds an MBA from Harvard Business School.

Warren Watson

Warren Watson is a medical device executive with over 40 years of med tech experience. His career began with Medtronic, where he served in capacities of increasing responsibility over greater than 30-year tenure. Warren focused in the Cardiac Rhythm Management, Cardiac Ablation, Heart Failure and Cardiology fields, including positions in technical management, clinical and regulatory, business development, strategy, marketing, and general management. He served as Vice President of Research and Development for the Cardiac Rhythm Management business for over 8 years and was Chair of the Medtronic Corporate Research and Development Council. Prior to that role, Warren served as General Manager of multiple Medtronic businesses and was the first Vice President of Marketing for Medtronic’s Tachyarrhythmia Business. He retired from Medtronic after 33 years of service to the company.
Mr. Watson serves on the board for CHF Solution (NASDAQ: CHFS), Cardialen, Children’s Specialty Healthcare, Gillette, Nuax, University of Minnesota Center for Autoimmune Disease Research, and University of Minnesota Office of Technology Commercialization. He previously served on the board of Cameron Health (as Executive Chairman), CardioMems, CloSys, Citizens Independent Bank of St. Louis Park, Continua Consortium, Excigen, Endocardial Solutions, Mardil Medical, Survivalink. Warren received his BS and MS degrees in Electrical Engineering from the University of Minnesota.

Pat Wethington

Pat serves as the President and Chief Executive Officer of Stimdia Medical, a privately-held company that is developing products to treat patients with ventilator-induced diaphragmatic dysfunction (VIDD). He was previously the Chief Executive Officer and President of CardioInsight Technologies (acquired by Medtronic), as well as the Chief Executive Officer and President of Hemosphere, a leading medical device company focused on cardiac and vascular surgery (acquired by CryoLife). Pat possesses more than 25 years of cross-functional medical device experience in the cardiovascular industry, including leadership roles at Guidant (acquired by Boston Scientific), Endocardial Solutions (acquired by St. Jude Medical), St. Jude Medical, and CHF Solutions (acquired by Gambro).
Pat possesses a BA from Clemson University and a MBA from the Carlson School of Management at the University of Minnesota.

Rubal Bedi

Rubal Bedi is an Investment Director at Ascension Ventures where he primarily focuses on investments in the medical device and diagnostics sector. Prior to joining Ascension in 2016, Rubal served for nearly a decade at Medtronic, where he led business development and strategy within the Aortic and Peripheral Vascular division, a $1.6 billion business unit. While he was at Medtronic, Rubal led investments in Shockwave Medical and Arsenal Medical. Previously, Rubal worked at PTV Healthcare Capital, a late-stage venture and growth equity firm. During his time there, Rubal worked with the entrepreneur in residence in the formation of Apollo Endosurgery (NASDAQ: APEN).
Rubal serves on the boards of Bardy Diagnostics and Neuronetics. Previously, he has served on the boards of TVA Medical and 480 Biomedical. He received an MBA from the McCombs School of Business at the University of Texas at Austin and a BA in Economics from the University of California at Irvine.


SV Health Investors

SV Health Investors (formerly SV Life Sciences) is a healthcare and life sciences venture capital and growth equity firm. SV targets early-stage opportunities in biotechnology; early-stage and revenue-stage opportunities in medical devices; and growth equity investments for later-stage businesses in healthcare services and digital health. Over the past 20 years, SV Health Investors has invested in more than 175 companies. The firm currently has over $2.5 billion of capital commitments under management. SV Health Investors has offices in Boston, San Francisco, and London. For more information, please visit https://www.svhealthinvestors.com.

Health Enterprise Partners

Health Enterprise Partners (HEP) invests primarily in privately held, middle market companies in health care services and health care information technology. Central to HEP’s strategy is its unique and extensive hospital system and health plan network, 26 members of which are investors in HEP’s funds. HEP seeks to invest in companies that improve the quality of the patient experience, expand access, and reduce the cost of health care. For more information, please visit http://www.hepfund.com.

Ascension Ventures

Ascension Ventures is a strategic healthcare venture firm with more than $800 million in capital under management. The firm is a wholly owned subsidiary of Ascension, the nation’s largest Catholic and non-profit health system. Ascension Ventures’ role is to construct and manage a strategic portfolio of investments that deliver venture-level investment returns, have the potential to transform the healthcare industry, and significantly enhance the experience for patients, their families and their caregivers. Its health system limited partners operate 474 hospitals, have 578,000 employees and generate $88 billion in annual revenue. For more information, please visit http://www.ascensionventures.org.

Square 1 Bank

Square 1 Bank is a division of Pacific Western Bank, a Los Angeles-based commercial bank with over $21 billion in assets. A full service financial services partner to entrepreneurs and their investors, Square 1 provides clients flexible resources and attentive service to help their companies grow. Square 1 offers a broad range of venture debt, treasury and cash management solutions through offices in top innovation centers: Atlanta, Austin, the Bay Area, Boston, Chicago, Denver, Durham, Los Angeles, Minneapolis, New York, San Diego, Seattle and Washington, DC. Pacific Western Bank is a wholly-owned subsidiary of PacWest Bancorp. For more information, please visit https://www.square1bank.com.